| Name | Title | Contact Details |
|---|
We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
Vista Pharmaceuticals is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CPEX Pharmaceuticals is a Exeter, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Global CINRG is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.